Mario Cooper

Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses

N. Muzyczka, L. Govindasamy, M. Agbandje-McKenna, 2008, Proceedings of the National Academy of Sciences.

Regulatory T cells and TLR9 activation shape antibody formation to a secreted transgene product in AAV muscle gene transfer.

L. Morel, R. Herzog, C. Terhorst, 2017, Cellular immunology.

Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B.

H. Ertl, R. Herzog, K. High, 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer.

R. Herzog, C. Terhorst, O. Cao, 2009, Human gene therapy.

Portal vein delivery of viral vectors for gene therapy for hemophilia.

R. Herzog, D. Bellinger, T. Nichols, 2014, Methods in molecular biology.

Tolerance Induction to Cytoplasmic β-Galactosidase by Hepatic AAV Gene Transfer — Implications for Antigen Presentation and Immunotoxicity

B. Byrne, R. Herzog, D. Markusic, 2009, PloS one.

The lipofuscin fluorophore A 2 E perturbs cholesterol metabolism in retinal pigment epithelial cells

L. Govindasamy, A. Gleiberman, S. Zolotukhin, 2008 .

Prophylactic immune tolerance induced by changing the ratio of antigen‐specific effector to regulatory T cells

R. Herzog, Shangzhen Zhou, O. Cao, 2009, Journal of thrombosis and haemostasis : JTH.